For the full year of fiscal 2023, Lightspeed now expects an Adjusted EBITDA loss1 of approximately ($37) million, improved from previously-established outlook of approximately ($40) million. The Company now expects annual revenue to come in at the low end of the previously established outlook of $730 – $740 million (or approximately $740 million – $750 million on a constant currency basis1).
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a market capitalization of $3.91 billion.
